Armed with updated 24-week PhIII data, GBT convinces FDA to review sickle cell drug under accelerated pathway
In yet another sign of the FDA’s enhanced flexibility under commissioner Scott Gottlieb, Global Blood Therapeutics $GBT has managed to convinced the regulator to allow …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.